Products / Oncology & Hematology
Hereditary Cancers
Many types of hereditary cancer exhibit genetic heterogeneity, and simultaneous analysis of multiple genes is required to make an accurate diagnosis.
Especially in cases where there are clear clinical findings and a family history, using broad gene panels allows for rapid and comprehensive results by screening many genes associated with a cancer type at the same time.
ASCO (American Society of Clinical Oncology): Advocates for genetic testing in situations where it will directly impact patient management. It also recommends that the testing process be supported by clinical genetic counseling and that the results be integrated into the treatment plan.
ESMO (European Society for Medical Oncology): Supports the use of multi-gene panels. It emphasizes the importance of genetic information in treatment decisions and risk management, prioritizing the integration of this information into clinical decisions.
NCCN (National Comprehensive Cancer Network): Recommends genetic testing for individuals at risk of hereditary cancer based on factors such as family history, age, tumor type, and ethnicity. It emphasizes the use of broad panels covering genes such as BRCA1/2, MLH1, MSH2, MSH6, PMS2, and EPCAM.
SOPHiA DDM for Hereditary Cancers
Developed to assess hereditary cancer risks, this platform accurately screens for many high-risk genes, primarily BRCA1/2, using multi-gene panel analysis.
SOPHiA DDMTM makes hereditary cancer analysis reliable and standardized thanks to its powerful algorithms that support variant classification and clinical interpretation.
80+
Genes
ACMG
Classification
Clinical
Report
Variant
Filtering
AI-Powered Analysis
Guideline-based
Approach